Syndicate content

Archive - Jul 5, 2020

Date

International Society for Extracellular Vesicles (ISEV) 2020 Virtual Annual Meeting, Including Exosomes, July 20-22: Plenary Speakers, Panel Sessions, Oral Abstract Talks, Poster Chats, & Educational Sessions; FOCUS: PLENARY SPEAKERS

The International Society for ExtracellularVesicles (ISEV) AnnualMeeting (ISEV2020), Including #Exosomes, Is Now VIRTUAL (July 20-22); and will feature over 600 Discussions (Plenary Addresses, Panel Sessions, Oral Abstract Talks, Poster Chats, & Educational Sessions). The program can viewed here (https://www.isev.org/mpage/2020Program) and registration can be done here (https://www.isev.org/mpage/2020Registration). As eminent Yale professor Philip Askenase, MD, has said, “Exosomes are a sensational biological discovery and they seem to be involved in nearly all biological and clinical processes.” Please attend the virtual ISEV 2020 meeting to learn more about these fascinating and immensely important tiny particles. The 2020 virtual meeting will feature five plenary speakers who are acknowledged leaders in the field of extracellular vesicles (EVs). They are Alain Brisson, currently Emeritus Professor at the University of Bordeaux, in the team Extracellular Vesicles & Membrane Repair in CNRS unit CBMN; Hollis Cline, PhD, the Hahn Professor of Neuroscience and Co-Chair of the Department of Neuroscience at Scripps Research in La Jolla, California; Phylis Hanson, MD, PhD, the Minor J. Coon Collegiate Professor of Biological Chemistry and Chair of Biological Chemistry at the University of Michigan; Eduardo Marban, MD, PhD, Founding Director, Cedars-Sinai Heart Institute; and Shannon Stott, PhD, Assistant Professor, Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Associate Member, Broad Institute. Additional information on each of the ISEV 2020 plenary speakers is provided below.

ALAINE BRISSON, PHD

Label-Free Sensing of MCT1 and CD147 in Surface of Glioma-Derived Exosomes May Be Used for Tracking Metabolic Reprogramming and Malignant Progression in Glioma; Study Suggests Inhibitors of MCT1 & CD147 May Be Effective In Treating Gliomas

Researchers at the City University of Hong have demonstrated that malignant glioma cells release large numbers of exosomes containing high levels of MCT1 (monocarboxylate transporter 1) and its ancillary protein CD147 (cluster of differentiation 147). High levels of these two proteins are known to occur in malignant glioma and are associated with the tumor’s reprogramming to glycolysis (Warburg effect) as a rapid source of energy in a hypoxic environment. The authors showed that malignant glioma cells (GMs) release tremendous numbers of exosomes (nanovesicles of 30 nm to 200 nm in size), which promote tumor progression by the transport of pro-oncogenic molecules to neighboring cells. In their study, the authors found that hypoxia-induced malignant GMs strongly enhanced MCT1 and CD147 expression, playing a crucial role in promoting calcium-dependent exosome release. The hypoxic-GMs-derived exosomes contained significantly high levels of MCT1 and CD147, which could be quantitatively detected by noninvasive localized surface plasmon resonance (LSPR) and atomic force microscopy (AFM) biosensors, demonstrating that MCT1 and CD147 could be used as precise surrogate biomarkers for tracking parent GMs’ metabolic reprogramming and malignant progression as liquid biopsies. These new results were published on June 26, 2020 in Science Advances. The open-access article is titled “Label-Free Sensing of Exosomal MCT1 And CD147 for Tracking Metabolic Reprogramming and Malignant Progression in Glioma.” In the introduction to this article, the authors noted that glioma is the most common type of brain cancer and that it originates predominantly from neuroglial stem cells.